Gilead, Sangamo strike $3B off-the-shelf CAR-T deal – FierceBiotech
FierceBiotech |
Gilead, Sangamo strike $3B off-the-shelf CAR–T deal
FierceBiotech Gilead's Kite has struck a $3 billion deal to access Sangamo Therapeutics' zinc finger nuclease (ZFN) technology. Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR–T therapies to cement its position as a long-term … Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR–T Boost Kite, Sangamo Launch Up-to-$3B+ Cancer Cell Therapy Partnership Gilead is making a $3.1 billion bet on an experimental editing technology for cancer treatments |
